Argentina's first empirical readout on its 62-day approval cap is overdue, Brazil's reliance-queue checkpoint passed without published metrics, and another minimally invasive neural-interface program chose Melbourne over LATAM for first-in-human work. Plus the UK's new clinical trial framework, Bolivia joining the LATAM FIH map, and a fresh FIFARMA innovation environment study.
Argentina · Brazil · Bolivia · United Kingdom · Regional
bioaccess(R) | Global Trial Accelerators(TM) | Fast-Tracking First-in-Human Trials, Anywhere
Read the full newsletter online here.
---
This week the gap between Latin America's regulatory promise and the data needed to prove it grew harder to ignore. Argentina's first empirical readout on its 62-day approval cap is overdue, Brazil's reliance-queue checkpoint passed without published metrics, and another minimally invasive neural-interface program chose Melbourne over LATAM for first-in-human work.
Take a closer look at where first-in-human work is actually moving.
---
Phantom Neuro received approval on April 15 for the CYBORG Early Feasibility Study of its Phantom X minimally invasive muscle-machine interface, with up to 10 upper-limb amputees enrolled at Cabrini Health and ProMotion Prosthetics in Melbourne. The company's CEO publicly cited "Australia's efficient early-stage clinical trial pathways" as the reason for the site selection -- a framing now familiar to any LATAM-focused operator. The program's eventual U.S. pivotal phase remains an open question.
Why It Matters: Every neurotechnology FIH that lands in Australia rather than Latin America is a data point against the region's competitive case. Closing the gap requires not only fast statutory caps but published evidence that those caps hold in practice.
Argentina's Disposicion 7516/2025 -- the rule that capped ANMAT clinical trial reviews at 62 calendar days -- has been operative since December 1, 2025. Trials submitted in the first weeks after the rule took effect should now have completed the cycle, which means Q2 2026 ought to deliver the first meaningful comparison between the statutory clock and the operational one. As of April 27, ANMAT had not yet published that data.
Bottom Line: This is the single most consequential data point of the quarter. If the cap holds in practice, Argentina becomes the fastest FIH jurisdiction in Latin America. If it slips, the region's headline regulatory reform will have to be argued on aspiration rather than evidence.
April 14 was the first scheduled processing checkpoint for ANVISA's dedicated reliance queue under RDC 997/2025. Two weeks later, the agency has released no queue statistics, no average processing times, and no public assessment of how the new Plano de Gestao da Avaliacao roadmaps are performing.
What to Focus On: Sponsors with prior FDA or EMA approval are watching for a reliance pathway that finishes inside 90 business days. Until ANVISA publishes the queue data, that promise remains an internal one.
The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 take effect on April 28, 2026. The new framework combines ethics and MHRA review into a single decision, introduces risk-proportionate notifications for lower-risk studies, mandates public registration, and requires patient-centric communication.
Why It Matters: Sponsors using Latin America as the speed leg of a UK-anchored multi-country program should map their LPLV dates against the April 28 cutover.
In the past week, bioaccess(R) published four Bolivia-focused guides in four days -- covering investigational device exemption submission, clinical trial outsourcing, and the AGEMED regulatory pathway. The cadence signals an operational position bioaccess(R) has been building quietly: Bolivia as a fifth LATAM FIH option alongside Argentina, Brazil, Colombia, and the Panama-Mexico corridor.
Bottom Line: A wider LATAM map gives sponsors more leverage on cost, recruitment, and competitive site density -- provided the regulatory clock can be characterized accurately.
On April 26, the Latin American Federation of the Pharmaceutical Industry published a new study on the region's health innovation environment, covering scientific capacity, clinical research capacity, and regulatory readiness. The federation's Latam Health Champions program drew 234 applications from 11 countries this cycle, with eight winners scheduled to present in Boston later this year.
What to Focus On: Sponsors evaluating LATAM feasibility now have an institutional data point to triangulate against agency timelines, site networks, and patient access.
bioaccess(R) | Fast-Tracking First-in-Human Trials, Anywhere.
← All Global Trial Accelerators editions · Contact bioaccess®